Nordson Corporation · NASDAQ:NDSN

Nordson — Q4 2024 Earnings Presentation

20 slides from Nordson's earnings presentation, Dec 12, 2024

  1. Slide 1: 4Q & Full-Year Fiscal 2024 Webcast

    4Q & Full-Year Fiscal 2024 Webcast December 12, 2024 NBS NEXT OWNER MINDSET WINNING TEAMS

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as

  3. Slide 3: Agenda

    Agenda 4Q and Full-Year Fiscal 2024 Webcast – December 12, 2024  4th Quarter and Full-Year Highlights  Enterprise Performance  Sales Performance and Earnings Review  FY 2025 and 1Q 2025 Guidance  Balance Sheet and Cash Flow  Q&A Sundaram Nagarajan Dan Hopgood Lara Mahoney President & Executive

  4. Slide 4: Highlights

    Highlights Strong execution and  Ascend Strategy making progress NBS Next driving record sales and EBITDA  FY 2024 Results:  Record sales for the fourth year in a row  Record EBITDA and EBITDA Margin  Strong cash flow  Consistent performance in dynamic environment 4

  5. Slide 5: Total Company – 4Q 2024

    Total Company – 4Q 2024 4Q 2024 Sales Bridge ** Sales $6 $744 $41  Reported sales increased 4% $719  Acquisitions contributed 6% and favorable currency impact contributed 1% $(22)  Organic decrease of 3% driven by tough comparisons in Industrial Precision Solutions segment and weakness in Medical

  6. Slide 6: Industrial Precision Solutions – 4Q 2024

    Industrial Precision Solutions – 4Q 2024 4Q 2024 IPS Sales Bridge** $405 Sales $4 $392 $5  Sales of $392 million, a 3% decrease $(22)  Organic decrease of 5% partially offset by 1% acquisition growth and 1% favorable currency impact  Strength in nonwovens product lines offset by tough comparisons

  7. Slide 7: Medical and Fluid Solutions – 4Q 2024

    Medical and Fluid Solutions – 4Q 2024 4Q 2024 MFS Sales Bridge ** Sales $36 $1 $200 $169  Sales of $200 million, an increase of 19% $(5)  Organic decrease of 3%, offset by acquisition contribution of 21% and favorable currency impact of 1%  Organic sales decrease was driven by softness in medical

  8. Slide 8: Advanced Technology Solutions – 4Q 2024

    Advanced Technology Solutions – 4Q 2024 4Q 2024 ATS Sales Bridge** Sales $145 $6 $1 $152  Sales of $152 million, an increase of 5%  4% organic growth; 1% favorable currency impact  Organic sales growth was driven by test and inspection and electronics dispense product lines 4Q 2023 Organic Curren

  9. Slide 9: Total Company – Fiscal 2024

    Total Company – Fiscal 2024 Full Year Sales** $125 $2,690 Annual Sales $2,629  Record annual sales of $2.7 billion, an increase of 2%  Acquisitions contributed 5% growth and currency impact $(65) was neutral  Organic decrease of 3% driven by the ATS segment, offset by relatively flat IPS and MFS

  10. Slide 10: Balance Sheet and Cash Flow

    Balance Sheet and Cash Flow Healthy Cash Flow with Sufficient Liquidity to Invest in Strategic Initiatives Free Cash Flow Net Debt  Cash flow of $492 million, which is a conversion rate of  Cash totaled $116 million 105% of net income  2.5x net debt leverage ratio based on trailing 12-month  In-

  11. Slide 11: Competitive Advantages

    Competitive Advantages Diversified, Niche High Recurring Direct to Customer End Markets Revenue Differentiated Growth-biased NBS Next Growth Products Portfolio Framework Leadership position in niche end markets 11 with differentiated products

  12. Slide 12: 2025-2029 Financial Targets

    2025-2029 Financial Targets Growth Compounder Revenue Adjusted EPS Growth Growth 6-8% 10-12% Average annual growth Engaged Employees Driven by Nordson Values 12

  13. Slide 13: 2025 End Market Visibility

    2025 End Market Visibility Industrial Precision Solutions Medical and Fluid Solutions Advanced Technology Solutions • Challenging comparisons in polymer • Supply chain adjustments continue in • 4Q 2024 YOY growth, but remaining processing and industrial product lines interventional solutions prudent

  14. Slide 14: 2025 Fiscal Full-Year Guidance

    2025 Fiscal Full-Year Guidance Full-year Sales Guidance Full-Year Growth from Record 2024 $2,750 - $2,870  Ascend strategy is advancing and delivering results  Backlog, including Atrion, is ~$580 million $2,689 $2,629  Fiscal 2025 sales growth of 2% to 7%, inclusive of FX headwind of (1.5)%  Adj

  15. Slide 15: 2025 Fiscal 1Q Guidance

    2025 Fiscal 1Q Guidance 1Q 2025 Revenue Guidance Conservative expectations for 1Q $633 $615 - $655 $611  1Q 25 sales of $615 - $655 million  1Q 25 adjusted earnings per share in the range of $1.95 - $2.15  Considerations: Global macro-environment, seasonally weaker 1Q historically, end market unc

  16. Slide 16: Questions?

    Questions? Ciordson

  17. Slide 17: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Net Income to Adjusted EBITDA (Dollars in thousands) 17

  18. Slide 18: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Adjusted Operating Profit and EBITDA (Dollars in thousands) 18

  19. Slide 19: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Profitability (Dollars in thousands) 19

  20. Slide 20: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Operating Cash Flow to Free Cash Flow 20

Nordson — Q4 2024 Earnings Presentation on 6ix